{
  "title": "Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.",
  "pmid": "40097400",
  "doi": null,
  "affiliations": [
    "Department of Radiation Oncology, Gustave Roussy, Villejuif, France. antonin.levy@gustaveroussy.fr.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France. antonin.levy@gustaveroussy.fr.",
    "Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France. antonin.levy@gustaveroussy.fr.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France. antonin.levy@gustaveroussy.fr.",
    "Department of Radiation Oncology, Gustave Roussy, Villejuif, France.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France.",
    "Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France.",
    "Oncostat 1018 Inserm, University Paris-Saclay, Villejuif, France.",
    "Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.",
    "Department of Radiation Oncology, Gustave Roussy, Villejuif, France.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France.",
    "Bioinformatic platform, Gustave Roussy, Villejuif, France.",
    "Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.",
    "Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France.",
    "Department of Radiation Oncology, Gustave Roussy, Villejuif, France.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France.",
    "Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France.",
    "Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France.",
    "Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France.",
    "Department of Interventional Radiology, Gustave Roussy, Villejuif, France.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France.",
    "Oncostat 1018 Inserm, University Paris-Saclay, Villejuif, France.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France.",
    "Department of Radiation Oncology, Gustave Roussy, Villejuif, France.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France.",
    "Gustave Roussy, Inserm U1015, Université Paris-Saclay, Villejuif, France.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France.",
    "Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France.",
    "Drug Development Department (DITEP) Gustave Roussy-Cancer Campus, Villejuif, France.",
    "Sarcoma unit, Gustave Roussy, Villejuif, France.",
    "Drug Development Department (DITEP) Gustave Roussy-Cancer Campus, Villejuif, France.",
    "Department of Radiation Oncology, Gustave Roussy, Villejuif, France. eric.deutsch@gustaveroussy.fr.",
    "Gustave Roussy, Inserm U1030, Université Paris-Saclay, Villejuif, France. eric.deutsch@gustaveroussy.fr.",
    "Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France. eric.deutsch@gustaveroussy.fr."
  ]
}